Язвенный колит и рак толстой кишки: формирование групп риска, скрининг и профилактика


Н.В. Никитина, Е.А. Белоусова

Известно, что язвенный колит (ЯК) ассоциируется с повышением риска рака толстой кишки (РТК). В обзоре рассматриваются факторы риска развития РТК при ЯК (продолжительность заболевания, протяженность воспаления в толстой кишке, первичный склерозируюший холангит и др.), общие принципы скрининга и ведения больных с наличием этих факторов. Приводится информация о молекулярных механизмах возникновения РТК при ЯК и современных методах его диагностики. Обсуждаются подходы к профилактике РТК у больных ЯК (колэктомия, хемопрофилактика). Отмечается, что для предупреждения РТК должна использоваться длительная терапия препаратами 5-аминосалициловой кислоты, в первую очередь месалазином. Перспективным представляется и применение с этой целью урсодеоксихолевой кислоты.

Литература






  1. Аруин Л.О., Капуллер Л.Л., Исаков В.И. Морфологическая диагностика болезней желудка и кишечника. М., 1998. 496 с.
  2. Белоусова Е.А. Язвенный колит и болезнь Крона. М., 2002. 128 с.
  3. Белоусова Е.А., Златкина А.Р., Казанцева И.А., Исаков В.А. Пролиферативная активность толстокишечного эпителия при язвенном колите // Материалы научной сессии ЦНИИГ. М., 1998.
  4. Киркин Б.В., Капуллер Л.Л., Маят К.Е. и др. Рак толстой кишки у больных неспецифическим язвенным колитом // Клин. мед. 1988. № 9. С. 108–113.
  5. Никитина Н.В. Диагностическое и прогностическое значение тканевых эмбриональных антигенов при язвенном колите // Автореф. дисс. канд. мед. наук. М., 1999. 24 с.
  6. Ahnen DJ, Warren GH, Greene LJ, et al. Search of a specific marker of mucosal dysplasia in chronic ulcerative colitis. Gastroenterology 1987;93:1346–55.
  7. Allgayer H, Kruis W. Aminosalicylates: Potentional antineoplastic action in cjljn cancer prevtntion. Scand J Gastroenterol 2002;37(2):125–31.
  8. Allan RN. Cancer risk in ulcerative colitis and Crohn’s disease. Inflammatory bowel disease. Ed. by G Jarnerot 1992, p. 551–68.
  9. Befrits R, Hammarberg C, Rubio C, et al. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum 1994;37:313–20.
  10. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patiens the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71–76.
  11. Binder V, Langholz E, Munkholm P. Intestinal cancer risk in patients with inflammatory bowel disease. Malignancy and chronic inflammation in the gastrointestinal tract – new concepts. Kluwer Academic Publishers 1995, p. 101–04.
  12. Brentnall TA. Risk factors for development of cancer in IBD. Int. symosium of IBD “Advances in inflammatory bowel diseases”. 1998;106:33.
  13. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107:369–78.
  14. Breuer-Katschinsky B, Nemes K, Rump B, et al. Long-term use of nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. Digestion 2000;61:129–34.
  15. Broome U, Lofberg R. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404.
  16. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine – induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999;13:1397–1402.
  17. Bus PJ, Verspaget HW, Lamers CB, et al. Chemopreventiion of colorectal cancer by non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 2000;35(suppl. 232):101–04.
  18. Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia and surveillance in patients with ulcerative colitis. N Eng J Med 1987;316:1654.
  19. Connel WR, Lennard-Jones JF, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934–44.
  20. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000;14:145–53.
  21. Eaden J, Abrams K, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526–35.
  22. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer, a population-based study. N Engl J Med 1990;323:1228–33.
  23. Ekbom A, Kornfeld D. Sulphasalazine use as a preventive factor for colorectal cancer in ulcerative colitis patients – a review (Clinical review). IBD 1996;2:276–78.
  24. Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-side ulcerative colitis: factors determining risk. Gastroenterology 1979;77:290.
  25. Hasegawa H, Ueda M, Watanabe M. K-ras gene mutations in early colorectal cancer. Oncogene 1995;10:1413–16.
  26. Hordjik ML, Chivananda S. Risk of cancer in inflammatory Bowel Disease: why are the results in the rewiewed literature so varied? Scand J Gastroenterol 1989;24:70–74.
  27. Ilias M, Tomlinson IPM, Hanby AM, et al. Bcl-2 expression in colorectal tumors. Evidence of different pathways in sporadic and ulcerative colitis – assotiated carcinomas. Am J Pathol 1996;149:1719–26.
  28. Infantolino D, Biasin MR, D’Inca R, et al. An immunohistochemical study crypt cell proliferation in ulcerative colitis. Inflammatory bowel diseases. Falk Symposium 1994;76:22.
  29. Jain SK, Peppersorn MA. Inflammatory bowel disease and colon cancer: a review. Dig Dis 1997;15:243–52.
  30. Kanemitsu T, Koike A, Yamamoto S. Study of the cell proliferation kinetics in ulcerative colitis, adenomatous polyps, and cancer. Cancer 1985;56:1094–98.
  31. Karlen P, Kornfeld D, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis: a population-based case control study. Gut 1998;42:711–16.
  32. Keller K, Koch MK. The use of proliferating cell nuclear antigen (PCNA) expression and intraepithelial lymphocyte count in the differential diagnosis of inflammatory bowel disease. Italian J Gastroenterol 1994;26:233–37.
  33. Kern SE, Redston M, Seymour AB, et al. Molecular genetic profiles of colitis-associated neoplasms. Gastroenterology 1994;107:420–28.
  34. Klump B, Holzmann K, Kuhn A, et al. Distribution of cell populations with DNA aneuploidy and p53 protein expression in ulcerative colitis. Eur J Gastroenterol Hepatol 1997;9:789–94.
  35. Kulmann F, Fadaie M, Gross V, et al. Expession of proliferating cell nuclear antigen (PCNA) and Ki 67 in dysplasia in inflammatory bowel disease. Gastroenterol Hepatol 1996;8:371–79.
  36. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444–51.
  37. Lennard-Jones JE, Melville DM, Morson BC, et al. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990;31:800–06.
  38. Levin B, Lennard-Jones J, Riddell RH, et al. Surveillance of patients with chronic ulcerative colitis. Bull World Health Org 1991;69:121.
  39. Lewis JD. Ursodiol prevents UC-assosiated CRC. Gasrtoenterology 2001;121:491.
  40. Lindberg B, Persson B, Veress B, et al. Twenty years colonoscopic surveillance of patients with ulcerative colitis. Scand J Gastroenterol 1996;31:1195–204.
  41. Matsuda K, Watanabe H, Ajioka Y, et al. Ulcerative colitis with overexpression of p53 preceding overt histological abnormalities of the epithelium. J Gastroenterol 1996;31:860–67.
  42. Meltzer SJ, Greenwald BD. Molecular biology of colitis – associated neoplasia. Malignancy and chronic inflammation in the gastrointestinal tract – new concepts. Kluwer Academic Publishers 1995, p. 141–52.
  43. Moody GA, Jayanthi V, Pobert CSJ, et al. Long-term therapy with sulphasalazine protects against colorectal cancer risk and compliance with treatment in Leicestershire Eur J Gastroenterol Hepatol 1996;8:1179–83.
  44. Nikitina N, Belousova E, Zlatkina A, Pugachev K. The algorithm of form the risk group of colorectal cancer in ulcerative colitis. International symposium of IBD, 2003.
  45. Nugent FW, Haggitt RC, GilpinP A. Cancer surveillance in ulcerative colitis. Gastroenterology 1991;100:1241–4.
  46. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994;107:117–20.
  47. Porschen R, Molsberger G, Borchard F, et al. Value of flow cytometry in the surveillance of patients with ulcerative colitis. Malignancy and chronic inflammation in the gastrointestinal tract – new concepts. Kluwer Academic Publishers 1995, p. 134–40.
  48. Reinacher Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 2000;32:245–54.
  49. Riddell RH, Goldman H, Ransohoff DE, et al. Dysplasia in inflammatory bowel disease. Hum Path 1983;66:669–78.
  50. Schpach W, Muller YG, Boxberger F, et al. Histological changes in the colonic mucosa following irrigation with short-chain fatty acid. Gastroenterol Hepatol 1997;9:163–68.
  51. Sengupta S, Tjandra JJ, Gibson PR. Diatary fiber and colorectal neoplasia. Dis Colon Rectum 2001;44:1016–33.
  52. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxigenase-2 inhibitor in familial adenomatous polyps. N Engl J Med 2002;342:1946–52.
  53. Sugita A, Sachar DB, Bodian C, et al. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age of onset on colitis-cancer interval. Gut 1991;32:167.
  54. Tung BY, Emond MJ, Haggitt RC. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89–95.Tonelli F, Dolara P, Batugnani G, et al. Effects of short chain fatty acids on mucosal proliferation and inflammation of ileal pouches in patients with ulcerative colitis and familial polyposis. Dis Colon Rectum 1995;38:974–78.



Бионика Медиа